BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1462168)

  • 1. Antifolates: the next generation.
    Fleming GF; Schilsky RL
    Semin Oncol; 1992 Dec; 19(6):707-19. PubMed ID: 1462168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifolates in clinical development.
    Takimoto CH
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antifolates in clinical development.
    Takimoto CH; Allegra CJ
    Oncology (Williston Park); 1995 Jul; 9(7):649-56, 659 DISC 660, 662, 665. PubMed ID: 8924375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate and antifolate pharmacology.
    Kamen B
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New analogues of methotrexate].
    Yoshimura A
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2133-9. PubMed ID: 1444480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pralatrexate - from bench to bedside.
    Zain JM; Marchi E
    Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
    Gonen N; Assaraf YG
    Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro.
    Strømhaug A; Warren DJ
    Cancer Chemother Pharmacol; 2000; 45(6):450-6. PubMed ID: 10854131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
    Sharma RC; Assaraf YG; Schimke RT
    Cancer Res; 1991 Jun; 51(11):2949-59. PubMed ID: 1674447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Antifolates: Pharmacology and Clinical Applications.
    Takimoto CH
    Oncologist; 1996; 1(1 & 2):68-81. PubMed ID: 10387971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of antifolate efficacy in a rat sarcoma model.
    Li WW; Lin JT; Chang YM; Schweitzer B; Bertino JR
    Int J Cancer; 1991 Sep; 49(2):234-8. PubMed ID: 1831805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.
    Gangjee A; Jain HD; Kurup S
    Anticancer Agents Med Chem; 2008 Feb; 8(2):205-31. PubMed ID: 18288923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antifolate drugs.
    Purcell WT; Ettinger DS
    Curr Oncol Rep; 2003 Mar; 5(2):114-25. PubMed ID: 12583828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
    Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
    Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H; Niethammer D; Jackson RC
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.
    Rots MG; Pieters R; Peters GJ; van Zantwijk CH; Mauritz R; Noordhuis P; Willey JC; Hählen K; Creutzig U; Janka-Schaub G; Kaspers GJ; Veerman AJ; Jansen G
    Blood; 1999 Nov; 94(9):3121-8. PubMed ID: 10556198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J; Nimec Z; Rhee M
    Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antimetabolites, II].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):19-26. PubMed ID: 8422184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
    Li WW; Lin JT; Schweitzer BI; Bertino JR
    Mol Pharmacol; 1991 Nov; 40(5):854-8. PubMed ID: 1719370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.